UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of January 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the ‘Company’)
Transaction notification
|
1.
|
Details
of PDMR/person closely associated with them
(‘PCA’)
|
|
a)
|
Name
|
David
Redfern
|
|
b)
|
Position/status
|
President
Corporate Development
|
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the
financial instrument
|
Ordinary
shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN:
GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 8 January on Ordinary Shares held within an
ISA
|
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£18.845
|
17
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date of
the transaction
|
2026-01-09
|
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|
1.
|
Details
of PDMR/person closely associated with them
(‘PCA’)
|
|
a)
|
Name
|
Victoria
Whyte
|
|
b)
|
Position/status
|
SVP
& Company Secretary
|
|
c)
|
Initial
notification/
amendment
|
Initial
notification
|
|
2.
|
Details
of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK
plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details
of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of the
financial instrument
|
Ordinary
shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN:
GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 8 January 2026 on Ordinary Shares held within an
ISA
|
|
c)
|
Price(s) and
volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£18.845
|
15
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|
Aggregated
volume
Price
|
|
|
e)
|
Date of
the transaction
|
2026-01-09
|
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
About GSK
GSK is
a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com.
Registered
in England & Wales:
No.
3888792
Registered
Office:
79 New
Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: 15
January 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
